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pts, increased charge time 8 pts, device advisory 4 pts, and to preserve battery 31 pts.
Changes were made during a total of 157 visits, or a mean of 2 visits/pt (range 0-7). Con-
clusions: Programming of tachycardia and bradycardia parameters are frequently per-
formed at outpatient ICD FU. Although TTM of ICDs may be a useful adjunct for FU, it will
not completely replace office visits based on the need for individualized device repro-
gramming.
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817-1 Comparative Change in the Left Ventricular Ejection 
Fraction in Patients Undergoing Biventricular 
Defibrillator Implantation Using Transvenous Coronary 
Sinus Versus Epicardial Left Ventricular Leads
Mandeep Bhargava, William Belden, David Burkhardt, Yaariv Khaykin, George Joseph, 
Atul Verma, Jenniffer Cummings, Nassir Marrouche, David O. Martin, Robert Schweikert, 
Walid I. Saliba, Patrick M. McCarthy, Bruce L. Wilkoff, Patrick J. Tchou, The Cleveland 
Clinic Foundation, Cleveland, OH
BACKGROUND: Cardiac resynchronization therapy with defibrillators (CRT-D) has
proven efficacy and mortality benefit in heart failure patients with a wide QRS complex.
Implantation of such devices can be achieved either using transvenous coronary sinus
leads or with epicardial left ventricular leads. OBJECTIVE: To evaluate the comparative
efficacy of epicardial LV leads with transvenous CS leads, if any, on the change in LVEF
in patients receiving CRT-Ds. METHODS AND RESULTS: 130 consecutive patients
underwent implantation of a BiV ICD. The patients were evaluated for the LVEF using
transthoracic echocardiogram 1 month before the device implant and then 1-3 months
after the implantation of the device. All patients included in the study had the RV lead
placed at the apex and the LV lead positioned either transvenously in the posterior or lat-
eral branch of the CS or an epicardial LV lead placed atthe corresponding surface of the
heart at surgery. The patients were divided into two groups. Group I included 96 patients
who underwent BiV ICD implantation using a transvenous CS lead. In this group the
mean LVEF improved from 18.6+6.8% to 21.4+8.1% (p value 0.03). Group II included 34
patients with a similar device implanted using an epicardial LV lead. The LVEF in this
group improved from a mean of 17.6±5.6% to 21.9±9.5% (p value 0.02). When compared
for the mean LVEF pre and post procedure, there was no significant difference between
the two groups (p values 0.26 and 0.36, respectively). The mean rise in the LVEF in the
two groups was 1.82±5.9% in patients with CS leads and 2.4±6.1% in patients with epi-
cardial LV leads and this was not statistically significant (p value 0.3). CONCLUSIONS:
There is comparable improvement in the LVEF in patients treated with CRT-D using either
transvenous coronary sinus leads or epicardial left ventricular leads. Epicardial LV lead
placement can be safely considered for cardiac resynchronization therapy in patients
undergoing open heart surgery or subsequent to a failed CS lead placement.
2:15 p.m.
817-2 Unique Diagnostics Identify Patients at Risk for Heart 
Failure Decompensation
Philip B. Adamson, Andrew L. Smith, William T. Abraham, Karen J. Kleckner, Melissa R. 
Rhodes, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background: Newer implantable CRT devices measure night heart rate (NHR) and heart
rate variability (HRV) on a daily basis. This retrospective analysis examined if these
device measurements were different for patients at risk for clinical events.
Methods: Heart failure decompensations were reviewed for the U.S. InSync III trial
patients. Patients in NYHA III/IV heart failure without traditional pacing indications were
enrolled. Patients were classified into three groups: 1) those with no decompensations
(No-HF), 2) those with decompensations not requiring hospitalization (Minor event), and
3) those with decompensations requiring hospitalization (Hosp). Weekly averages of
NHR and HRV were computed for the first 52 weeks post implant. Differences between
groups were tested using a repeated measures analysis.
Results: There were 126, 68, and 44 pts in the No-HF, Minor event, and Hosp groups,
respectively, with mean follow-up of 16.5 months. HRV averaged 89±26, 87±28, and
75±27 ms (p=.002, No-HF versus Hosp; p=.019, Minor versus Hosp). See figure. NHR
averaged 69±11, 70±9, and 74±11 bpm (p=.004, No-HF versus Hosp; p=.019, Minor ver-
sus Hosp). At baseline, the Hosp group had lower beta blocker usage and higher NYHA
class.
Conclusions: HRV and NHR, continuously derived from an implanted device, are differ-
ent in heart failure patients at higher risk for clinical events, suggesting that HRV and
NHR, in concert with traditional measures, may help stratify patients at risk for heart fail-
ure decompensation.
2:30 p.m.
817-3 Heart Rate Variability and Heart Rate Changes Induced 
by Biventricular Pacing in Advanced Heart Failure
Francois Regoli, Cecilia Fantoni, Francesco Giraldi, Michael Kloss, Silke Trautmann, 
Helmut U. Klein, Angelo Auricchio, University Hospital, Magdeburg, Germany
Background: Cardiac resynchronization therapy (CRT) is a novel therapy in patients
with heart failure (HF). Weekly monitoring of mean heart rate (HR), HR range, heart rate
variability (HRV), and daily physical activity of pts with CRT has not been investigated in
detail. 
Methods: Data stored on a CRT-D (Contak-Renewal II, Guidant, USA) implanted in 54
pts (mean age 60.6± 3.8 years, QRS 149.6 ± 6.8 msec, LVEF 19± 0.9%) with NYHA
class >II despite optimal pharmacological treatment, were reviewed. Over a period of 12
weeks, changes of minimum HR (HR min), mean HR, HR range (min to max), standard
deviation of mean R-R intervals (SDANN) and degree of physical activity done by each
patient, measured by Activity Log Index (AL) of the device, were analysed.
Results: CRT-D determined a significant decrease of minimum and mean HR (66.2 ± 16
vs 58.5± 2.1 and 78.6± 18.2 vs 72.2± 2.8 bpm, respectively, p<0.04) and a marked
increase of HR range (31.1± 11.7 vs 39.7± 9.8 bpm, p< 0.006) and SDANN (63.5± 29.4
vs 88.4± 19 msec, p<0.004). Moreover, after 12 weeks of continuous pacing, AL
increased from 4.3± 1.9 to 11.2± 2.6% units (p<0.001). Changes of each parameter over
12 weeks are reported in the graph. 
Conclusions: the Contak-Renewal II device allows continuous assessment of surrogate
parameters of autonomic-nerve system activity. CRT-D provided a clear decrease of sym-
pathetic activity with an increase of parasympathetic tone. Moreover, a higher degree of
physical activity after 12 weeks of pacing was noted. 
2:45 p.m.
817-4 Angiotensin-Converting Enzyme Inhibitors Reduce the 
Incidence of Implantable Cardioverter Defibrillator 
Therapy in Idiopathic Dilated Cardiomyopathy With 
Congestive Heart Failure
Fei Lu, Edmund Ang, Richard G. Trohman, David G. Benditt, Univeristy of Minnesota, 
Minneapolis, MN, Rush-Presbyterian-St Luke's Medical Center, Chicago, IL
Background: Clinical trials have shown favorable long-term effects of angiotensin-con-
verting enzyme (ACE) inhibitors on morbidity and mortality in patients with congestive
heart failure (CHF). ACE inhibitors may affect and modify the triggering factors and sub-
strates of ventricular arrhythmias and sudden cardiac death in these patients. This study
was aimed at examining the effects of ACE inhibitors on the incidence of defibrillator
(ICD) therapy in patients with CHF secondary to idiopathic dilated cardiomyopathy
(DCM).
Methods & Results: One hundred and two patients (aged 52±16 years) with idiopathic
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DCM who were treated with ICDs were enrolled in this study. Their left ventricular ejec-
tion fraction (LVEF) was 25±9%. During a regular followup period of up to 60 months
(median 21 months), these patients received frequent appropriate (34%) and inappropri-
ate (36%) ICD therapies. The first appropriate ICD therapy occurred at 7 months
(median). Approximately 2/3 of these ICD therapies occurred within one year after
implantation. There was no significant difference between patients on (n=81) and off ACE
inhibitors in age (51±16 vs 52±15 years, p>0.05), LVEF (25.5±8.8% vs 23.2±9.2%,
p>0.05), or incidence of documented spontaneous or inducible sustained ventricular
tachycardia / fibrillation before implantation (36% vs 48%, p>0.05). Fewer patients on
ACE inhibitors were treated with amiodarone (21% vs 48%, p<0.05). After adjustment of
age, gender, LVEF, use of antiarrhythmic drugs, and incidence of pre-implant docu-
mented spontaneous or inducible sustained ventricular arrhythmias, the incidence of
appropriate ICD therapy was significantly lower in patients on ACE inhibitors than those
off ACE inhibitors (log rank p<0.05). At one year after implantation, ACE inhibitor therapy
was associated with an 80% reduction in appropriate ICD therapy in these patients (18%
vs 33%, log rank p<0.05).
Conclusion: ACE inhibitor therapy may substantially reduce the incidence of appropriate
ICD therapy in patients with CHF secondary to idiopathic DCM. These observations sug-
gest that ACE inhibitors may have important direct and/or indirect antiarrhythmic actions.
3:00 p.m.
817-5 Implant Defibrillator Threshold Characteristics in an 
Implantable Cardioverter Defibrillator Population 
Receiving Cardiac Resynchronization Therapy
Claudio Schuger, Kenneth Ellenbogen, Mitchell Faddis, Bradley P. Knight, Patrick Yong, 
Ross Sample, The VENTAK CHF/CONTAK CD Study Investigators, Henry Ford Hospital, 
Detroit, MI, Guidant Corporation, St. Paul, MN
Background: Common practice during implantable cardioverter defibrillator (ICD)
implant is to perform defibrillation threshold (DFT) testing by converting induced ventricu-
lar fibrillation (VF) with a minimum 10-joule (J) safety margin. Patients (pts) with severe
left ventricular dysfunction may require additional energy to terminate VF and predicting
who is at risk for elevated DFTs would be of benefit.
Methods: Pts requiring ICD therapy, a history of congestive heart failure (NYHA Class II-
IV) and QRS >=120 ms were enrolled in the CONTAK CD study and received cardiac
resynchronization devices with ICD capability. The protocol recommended one of two
methods of DFT: either VF conversion testing with at least two successful conversions <=
21J or step down DFT testing. Multivariate logistic regression was performed to deter-
mine factors predictive of DFT test outcome.
Results: Of 501 pts enrolled, DFT recommendations were met in 444 (88.6%), with VF
conversion testing performed in 396 (79.0%) and step down DFT testing in 48 (9.6%)
with mean DFT of 10.7±4.6 J. DFT recommendations were not met in 57 pts (11.4%). Of
these, 31 pts (6.2%) had converted with energies >= 23J or had no DFT testing per-
formed due to pt condition and received a device without meeting implant recommenda-
tions. The remaining 26 pts (5.2%) began DFT testing, but terminated testing
prematurely due to pt condition. In the 31 pts with elevated or untested DFT, larger left
ventricular internal dimension in diastole (LVIDd) (p=0.003) and prolonged procedure
time (p=0.01) were significant predictors of higher energy requirements. Subcutaneous
arrays were used in nine pts (1.8%). Six met implant recommendations with its use, one
did not, and two pts were not tested.
Conclusion: DFT testing with adequate safety margin is accomplished successfully in
the majority of this high-risk ICD pt population. However, in a significant number of pts, a
10J safety margin cannot be ascertained. LVIDd and prolonged procedure time may pre-
dict higher DFT and could be used to anticipate the need for alternative shocking vectors
(such as subcutaneous array or patch electrode) or assuring the availability of a high-
energy device.
3:15 p.m.
817-6 Delineation of the Pericardiophrenic Vein for Optimal 
Left Ventricular Lead Placement
Marmar Vaseghi, David Cesario, Sen Ji, Kevin Shannon, Isaac Wiener, Gregg Fonarow, 
Jonah Odim, Miguel Valderrabano, Kalyanam Shivkumar, UCLA Cardiac Arrhythmia 
Center, Los Angeles, CA
Background: Biventricular pacing has established benefits for the management of drug
refractory heart failure. However, optimal placement of the left ventricular (LV) lead can
occasionally be associated with left phrenic nerve stimulation. The purpose of this study
was to define the value of identifying the pericardiophrenic vein, by venography or direct
visualization, for optimal LV lead placement. The pericardiophrenic vein runs along with
the left phrenic nerve and serves as a radiographic marker for sites with likely phrenic
nerve stimulation during LV lead placement. Methods: We analyzed data from 84
patients who underwent biventricular device implantation between July 2002 and Sep-
tember 2003. Eighty transvenous implants, one LV endocardial implant, and three surgi-
cal epicardial implants (including one previously failed transvenous implant) were
performed. Sixty five patients (77%) had ischemic cardiomyopathy. Results: In four
patients the pericardiophrenic vein was identified either during occlusion venography of
the CS (post thoracotomy, veno-venous collaterals, n=1) or during selective cannulation
of the pericardiophrenic vein (using a DAIG Csl catheter, n=3). The vein was directly visu-
alized in three patients who underwent surgical LV lead implantation. Whether placed in
the coronary veins or on the epicardium, LV leads in these cases were implanted in areas
not overlying the pre-identified pericardiophrenic vein. During follow-up, none of the
patients who had LV leads placed with prior delineation of the pericardiophrenic vein had
any evidence of phrenic nerve stimulation. However, three patients (4%) in whom the
pericardiophrenic vein was not identified developed phrenic nerve stimulation. Conclu-
sions: Identification of the pericardiophrenic vein is feasible in all patients undergoing
surgical LV lead placement, and with the aide of angiography, in selected patients under-
going transvenous LV lead implantation. Phrenic nerve stimulation by the LV leads can be
avoided by placement of the leads away from the previously identified pericardiophrenic
vein, reducing the incidence of phrenic nerve stimulation.
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1110-213 Ranolazine Attenuates Increased Variability of Action 
Potential Duration and After Depolarizations Caused by 
Augmentation of Late Sodium Current
Yejia Song, Lin Wu, John C. Shryock, Luiz Belardinelli, University of Florida, Gainesville, 
FL, CV Therapeutics, Palo Alto, CA
Background: This study assessed the hypothesis that an increase of late sodium current
(INa(L)) exacerbates beat-to-beat variability of action potential duration (APD) and facili-
tates the actions of potassium-channel blockers to induce early afterdepolarizations
(EADs).
Methods: INa(L) and action potentials (APs) of guinea pig isolated ventricular myocytes
were measured using whole-cell patch-clamp techniques.
Results: The INa(L) enhancer ATX-II (5 nmol/L) increased the amplitude of INa(L) by
217±39 pA (n=9, p<0.001). ATX-II (15 nmol/L) prolonged the APD measured at 50%
repolarization (APD50) by 244±24% from 281±11 to 963±61 ms (n=7, p<0.001) and
induced EADs. Moreover, ATX-II increased the variability of APD50 (SD/mean of 10 con-
secutive APs, x100) from 1.1±0.3 to 16.2±0.7% (n=7, p<0.001). Ranolazine (10 µmol/L),
an anti-ischemic agent and a putative inhibitor of INa(L), attenuated the ATX-II-induced
INa(L) by 37±3% (p<0.05). The inhibition by ranolazine of INa(L) was mimicked by tetrodot-
oxin (10 µmol/L, n=5). In the presence of ATX-II, Ranolazine (10 µmol/L) shortened the
APD50 to 378±34 ms (p<0.001), abolished the EADs, and reduced the variability of
APD50 to 2.8±0.4% (p<0.001). Although ATX-II at a low concentration (3 nmol/L)
increased the APD50 by only 6±2% (n=11), it facilitated the actions of E-4031 (1 µmol/L)
and chromanol 293B (30 µmol/L), blockers of the rapid and slow components of the
delayed rectifier potassium current, respectively, to prolong the APD50. In the absence
and presence of ATX-II, the APD50 was increased by 11±2% (n=6) and 104±41% (n=8)
by E-4031 (p<0.01), and 40±7% (n=6) and 202±59% (n=9) by 293B (p<0.001), respec-
tively. EADs were induced by E-4031 and 293B only in the presence of ATX-II. Ranola-
zine (10 µmol/L) abolished the EADs and reversed the prolongation of APD50 by 76±5%
(n=5, p<0.01) and 71±4% (n=9, p<0.001), respectively, in the presence of ATX-II plus E-
4031 or 293B.
Conclusion: An augmentation of INa(L) greatly increased the variability of APD and facil-
itated the proarrhythmic effects of potassium-channel blockers. Inhibition of INa(L), such
as by ranolazine, may reverse dispersion of repolarization, drug-induced QT prolonga-
tion, and arrhythmias.
1110-214 Ischemia/Reperfusion Induced Intracellular Calcium 
Oscillations in the Intact Heart: Relation to 
Arrhythmogenesis
Vikram Lakireddy, Paramdeep Baweja, Gil Bub, Tamara Baynham, Nabil El-Sherif, 
Downstate Medical Center, Brooklyn, NY, VA New York Harbor Health Care System, 
Brooklyn, NY
Background: Intracellular calcium (iCa) loading by various mechanisms, including
ischemia /reperfusion (I/R), has been postulated to cause spontaneous oscillatory Ca2+
release from the sarcoplasmic reticulum that may play a role in generation of arrythmia.
Thus far, this mechanism has been demonstrated in isolated cardiomyocytes or 2-dimen-
sional myocyte networks. We investigated the development of iCa oscillations (O) during
I/R in the intact heart.
Methods: Perfused Langendorff guinea pig hearts were subjected to global I/R (20 min./
20 min.). The heart was stained with 100 microliters of Rhod-2 AM and 25 microliters of
RH-327. Membrane voltage (Vm) and iCa were simultaneously recorded with an optical
mapping system of two 16x16 photodiode arrays. Activation maps of both Vm and iCa
were constructed.
Results: O at varying cycle lengths (200-600ms) were observed to develop at well local-
ized focal sites within the mapped surface where iCa signal preceded Vm signal by 10-
20ms. O that followed the iCa transient of a basic beat manifested in the Vm as early
afterdepolarizations. Intermittent conduction from the focal site of O to the rest of the
heart manifested as occasional premature beats , trigeminal, or bigeminal rhythm. A reg-
ular conduction pattern from a focal site of fast O manifested as regular tachycardia of
focal origin. A complex conduction pattern of fast O resulted in wavebreaks and induction
of ventricular fibrillation (VF).
Conclusion: We have shown, for the first time, the development of focal O during I/R in
the intact heart. Depending on the conduction pattern, O can result in a single premature
beat or regular tachycardia, or can induce VF. In the setting of I/R, an occasional prema-
ture beat may represent the “tip of the iceberg” of an underlying potentially serious arryth-
mogenic mechanism.
